Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) shares, rose in value on Thursday, April 16, with the stock price up by 4.48% to the previous day’s close as strong demand from buyers drove the stock to $0.23.
Actively observing the price movement in the last trading, the stock closed the session at $0.22, falling within a range of $0.2108 and $0.2261. The value of beta (5-year monthly) was 0.155. Referring to stock’s 52-week performance, its high was $4.00, and the low was $0.17. On the whole, CYCC has fluctuated by -26.14% over the past month.
With the market capitalization of Cyclacel Pharmaceuticals Inc currently standing at about $46.88 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Apr-01.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that CYCC’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of CYCC currently trading nearly -10.89% and -23.61% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 40.17, while the 7-day volatility ratio is showing 12.36% which for the 30-day chart, stands at 11.12%. Furthermore, Cyclacel Pharmaceuticals Inc (CYCC)’s beta value is 0.60, and its average true range (ATR) is 0.03.
A comparison of Cyclacel Pharmaceuticals Inc (CYCC) with its peers suggests the former has fared considerably weaker in the market. CYCC showed an intraday change of 4.48% in last session, and over the past year, it shrunk by -86.46%%.
Data on historical trading for Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) indicates that the trading volumes over the past 10 days have averaged 0.15 and over the past 3 months, they’ve averaged 316.46K. According to company’s latest data on outstanding shares, there are 207.34 million shares outstanding.
Nearly 93.87% of Cyclacel Pharmaceuticals Inc’s shares belong to company insiders and institutional investors own 0.34% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 55680.0 shares as on 2025-03-31, resulting in a short ratio of 0.25. According to the data, the short interest in Cyclacel Pharmaceuticals Inc (CYCC) stood at 44.00 of shares outstanding as of 2025-03-31; the number of short shares registered in 2025-02-28 reached 0.18 million. The stock has fallen by -39.87% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CYCC stock heading into the next quarter.
